evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

31 questions · 34 findings · 3 reviews · Hepato-Biliary

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 3 · 8.8%GRADE not reported 0 · 0%Very low 23 · 67.6%Low 4 · 11.8%Moderate 4 · 11.8%High 0 · 0%

Non‐absorbable disaccharides vs placebo or no intervention

All‐cause mortality · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Non‐absorbable disaccharides probably leads to lower mortality compared with placebo/no intervention (moderate certainty).

1 finding from 1 review

Non‐absorbable disaccharides vs placebo or no intervention

Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Non‐absorbable disaccharides probably leads to lower hepatic encephalopathy compared with placebo/no intervention (moderate certainty).

1 finding from 1 review

Non‐absorbable disaccharides vs placebo or no intervention

Serious adverse events · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Non‐absorbable disaccharides probably leads to lower serious adverse events compared with placebo/no intervention (moderate certainty).

1 finding from 1 review

Non‐absorbable disaccharides vs placebo or no intervention

Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether non‐absorbable disaccharides changes non‐serious adverse events (secondary outcome) compared with placebo/no intervention (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

Mortality ‐ total number · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin plus non‐absorbable… probably leads to lower mortality ‐ total number compared with non‐absorbable disaccharides alone (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin plus non‐absorbable… may leads to lower hepatic encephalopathy ‐ total number compared with non‐absorbable disaccharides alone (low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in hepatic encephalopathy ‐ total number compared with non‐absorbable disaccharide (low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Mortality ‐ total number · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in mortality ‐ total number compared with non‐absorbable disaccharide (low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (low certainty).

1 finding from 1 review

Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides

Blood ammonia concentrations (units unspecified) · adults with cirrhosis and hepatic encephalopathy
3 findings from 1 review